Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...